These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sucralfate maintenance therapy in duodenal ulcer disease. A review. Bolin TD Am J Med; 1989 Jun; 86(6A):148-51. PubMed ID: 2567571 [TBL] [Abstract][Full Text] [Related]
4. Reversible sustained increase of gastrin and gastric acid secretion in a subgroup of duodenal ulcer patients on long-term treatment with H2 antagonists. Kohn A; Annibale B; Prantera C; Giglio L; Suriano G; Delle Fave G J Clin Gastroenterol; 1991 Jun; 13(3):284-90. PubMed ID: 1676714 [TBL] [Abstract][Full Text] [Related]
5. The use of H2-receptor antagonist in the treatment of peptic ulcer disease in children. Tam PK; Saing H J Pediatr Gastroenterol Nutr; 1989 Jan; 8(1):41-6. PubMed ID: 2567346 [TBL] [Abstract][Full Text] [Related]
6. Economic and health aspects of peptic ulcer disease and H2-receptor antagonists. Jensen DM Am J Med; 1986 Oct; 81(4B):42-8. PubMed ID: 2877574 [TBL] [Abstract][Full Text] [Related]
7. Duodenal ulcer. Who should have long-term maintenance therapy? Zuckerman G Postgrad Med; 1987 Oct; 82(5):52-3, 57-8, 60. PubMed ID: 2890147 [TBL] [Abstract][Full Text] [Related]
8. Long-term treatment for gastric and duodenal ulcer. Di Mario F; Battaglia G; Pasqualetti P; Vio A; Gottardello L; Grassi SA Ital J Gastroenterol; 1990; 22 Suppl 2():24-8. PubMed ID: 1983413 [TBL] [Abstract][Full Text] [Related]
9. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection. Freston JW Am J Gastroenterol; 1987 Dec; 82(12):1242-9. PubMed ID: 2891294 [TBL] [Abstract][Full Text] [Related]
10. Long term treatment of duodenal ulcer. A review of management options. Bianchi Porro G; Parente F Drugs; 1991 Jan; 41(1):38-51. PubMed ID: 1706986 [TBL] [Abstract][Full Text] [Related]
11. The histological maturity of regenerating mucosa of healed duodenal ulcer and ulcer recurrence after treatment with H2-antagonist. Pan S; Liao CH Am J Gastroenterol; 1990 Aug; 85(8):949-52. PubMed ID: 1973870 [TBL] [Abstract][Full Text] [Related]
12. The H2-receptor antagonist era in duodenal ulcer disease. Marks IN Yale J Biol Med; 1992; 65(6):639-48;discussion 689-92. PubMed ID: 1364125 [TBL] [Abstract][Full Text] [Related]
13. [Sulglycotide combined with H2-antagonists in the prevention of duodenal ulcer recurrence. Multicenter study]. Ciaco A; Papi C; Capurso L Minerva Gastroenterol Dietol; 1992; 38(3):153-9. PubMed ID: 1363719 [TBL] [Abstract][Full Text] [Related]
14. Nizatidine as maintenance therapy of duodenal ulcer disease in remission. Cerulli MA; Cloud ML; Offen WW; Chernish SM; Matsumoto C Scand J Gastroenterol Suppl; 1987; 136():79-83. PubMed ID: 2892259 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects and after-effects of treatment of duodenal ulcer with metiamide. Saunders JH; Wormsley KG Lancet; 1977 Apr; 1(8015):765-7. PubMed ID: 66567 [TBL] [Abstract][Full Text] [Related]
17. The natural history of peptic ulcer disease: the influence of H2-antagonist treatment. Bianchi Porro G; Petrillo M Scand J Gastroenterol Suppl; 1986; 121():46-52. PubMed ID: 2876513 [TBL] [Abstract][Full Text] [Related]
18. Impact of H2-receptor antagonists on the outcome of treatment of perforated duodenal ulcer. Macintyre IM; Millar A J R Coll Surg Edinb; 1990 Dec; 35(6):348-52. PubMed ID: 1982317 [TBL] [Abstract][Full Text] [Related]
19. H2-blockers: how safe and how effective? Spiro HM J Clin Gastroenterol; 1983; 5 Suppl 1():143-7. PubMed ID: 6140282 [TBL] [Abstract][Full Text] [Related]
20. H2 receptor antagonist or H. pylori eradication? Ahmed W; Qureshi H; Syed S; Alam E; Zuberi SJ J Pak Med Assoc; 1992 Apr; 42(4):81-2. PubMed ID: 1350800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]